Retrotrapezoid neurons identified as key target in fentanyl respiratory depression

According to the study authors, including Thiago S. Moreira, PhD, retrotrapezoid nucleus (RTN) neurons in the brainstem retain functional capacity during fentanyl administration and represent a viable therapeutic target for reversing opioid-induced respiratory depression (OIRD), the primary cause of death in opioid overdose.¹ Published in the American Journal of Physiology, the findings identify a neural circuit whose stimulation can restore normal breathing even after fentanyl exposure, opening a mechanistic path toward non-opioid interventions for overdose rescue.

OIRD is characterized by severe suppression of respiratory rate, destabilized breathing patterns, hypercapnia, and heightened risk of fatal apnea.¹ Fentanyl, a synthetic opioid substantially more potent than morphine, presents an elevated OIRD risk compared with other opioids, in part through its tendency to cause chest wall rigidity and laryngeal closure. Naloxone remains the primary overdose reversal agent, but its short half-life relative to fentanyl’s duration of action creates a re-narcotization risk, and the need for repeated dosing in high-dose fentanyl exposures has driven interest in alternative or complementary mechanisms for respiratory rescue.

Researchers from the University of São Paulo and Seattle Children's Research Institute focused on the RTN, a chemosensitive brainstem region in the rostral ventrolateral medullary reticular formation containing Phox2b+/Neuromedin-B (Nmb) propriobulbar neurons.¹ These neurons are normally stimulated by elevated CO₂/H⁺, serving as a critical chemosensory feedback mechanism to increase ventilation and prevent respiratory acidosis. Because RTN neurons show limited expression of opioid receptors, the investigators hypothesized they should remain responsive during opioid-induced hypoventilation.

Using optogenetic and chemogenetic tools in rodent models, the researchers demonstrated that stimulating RTN Phox2b+/Nmb+ neurons enhanced breathing even after fentanyl administration.¹ Conversely, inhibition of these neurons exacerbated fentanyl-induced hypoventilation. The results confirm RTN neurons retain functional capacity during opioid exposure and can be activated to counteract the respiratory depression produced by fentanyl acting on other brainstem circuits.

Implications for overdose pharmacology and non-opioid reversal strategies

The RTN finding is mechanistically distinct from naloxone’s mechanism, which competes for opioid receptor binding. A treatment strategy activating RTN neurons would not require displacing fentanyl from opioid receptors, addressing a key limitation of naloxone in high-dose fentanyl overdose scenarios where opioid receptor occupancy is high.¹ The study also demonstrated that stimulating RTN neurons partially restored eupneic breathing and sigh generation during fentanyl exposure, both of which are disrupted in OIRD.

For ID clinicians and infectious disease practitioners managing patients with OUD and comorbid infectious conditions, the research adds scientific grounding to the growing field of non-naloxone rescue strategies. Patients with HIV, HCV, or serious bacterial infections receiving opioids for pain management or presenting in acute fentanyl overdose in ED or inpatient settings represent a population where mechanistic alternatives to naloxone are clinically relevant.¹

The investigators noted RTN neurons serve as a potential lifeline by monitoring hypoxia and hypercapnia under fentanyl conditions, and their retained responsiveness despite opioid-induced suppression of other respiratory circuits positions them as a high-priority target for drug development efforts aimed at non-opioid-receptor-based respiratory rescue pharmacology.¹

References

1. Moreira TS, Burgraff NJ, et al. Functional modulation of retrotrapezoid neurons drives fentanyl-induced respiratory depression. Am J Physiol Lung Cell Mol Physiol. 2025;329(3):L357-L375. doi:10.1152/ajplung.00025.2025

2. Overdose Prevention Strategy. US Department of Health and Human Services. Accessed July 2026. https://www.hhs.gov/overdose-prevention/index.html